Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Plonquet A, Alonso MA, MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 2002;15:1172–1180.
   PubMed Web of Science ®Google Scholar
• Calaminici M, Piper K, Lee AM, Norton AJ. CD23 expression in mediastinal large B-cell lymphomas. Histopathology 2004;45:619–624.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871–3879.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851–862.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Bertini M, Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002;87:1258–1264.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Magagnoli M, Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)gallium scan in 50 patients. Blood 1999;94:3289–3293.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Stefoni V, Finolezzi E, Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma 2009;9:381–385.
   PubMedGoogle Scholar
• Savage KJ, Al-Rajhi N, Voss N, Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006;17:123–130.
   PubMed Web of Science ®Google Scholar
• Todeschini G, Ambrosetti A, Meneghini V, Mediastinal large-B-cell lymphoma with sclerosis: a clinical study of 21 patients. J Clin Oncol 1990;8:804–808.
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997;15:1646–1653.
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993;11:2306–2313.
   PubMed Web of Science ®Google Scholar
• Todeschini G, Secchi S, Morra E, Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90:372–376.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001;19:1855–1864.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Portlock CS, Straus DJ, Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005;130:691–699.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Alizadeh AA, Eisen MB, Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000;97:10209–10213.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Bereschenko O, Niu H, Molecular pathogenesis of non-Hodgkin's lymphoma: the role of BCL-6. Leuk Lymphoma 2003;44(Suppl. 3): S5–S12.
   PubMed Web of Science ®Google Scholar
• Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000;24:846–852.
   PubMed Web of Science ®Google Scholar
• Falini B, Fizzotti M, Pucciarini A, A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95:2084–2092.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Pileri SA, Gaidano G, Zinzani PL, Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003;162:243–253.
   PubMed Web of Science ®Google Scholar
• de Leval L, Ferry JA, Falini B, Shipp M, Harris NL. Expression of BCL-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol 2001;25:1277–1282.
   PubMed Web of Science ®Google Scholar
• Biasoli I, Morais JC, Soares de Jesus P, Pulcheri W, Nucci M, Spector N. Application of an adapted international prognostic index for aggressive non-Hodgkin's lymphomas: good discrimination and lower survival rates in Rio de Janeiro, Brazil. Oncol Rep 2001;8:441–444.
   PubMed Web of Science ®Google Scholar
• Wang S, Saboorian MH, Frenkel EP, Assessment of HER-2/neu status in breast cancer. Automated cellular imaging system (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 2001;116:495–503.
   Google Scholar
• Cazals-Hatem D, Lepage E, Brice P, Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (‘Groupe d'Etude des Lymphomes de l'Adulte’) study. Am J Surg Pathol 1996;20:877–888.
   PubMed Web of Science ®Google Scholar
• Falini B, Venturi S, Martelli M, Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. Br J Haematol 1995;89:780–789.
   PubMed Web of Science ®Google Scholar
• Savage KJ. Primary mediastinal large B-cell lymphoma. Oncologist 2006;11:488–495.
   PubMed Web of Science ®Google Scholar
• Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999;17:2479–2485.
   PubMed Web of Science ®Google Scholar
• Haioun C, Gaulard P, Roudot-Thoraval F, Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol 1989; 12:425–429.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002–1006.
   PubMed Web of Science ®Google Scholar
• Jacobson JO, Aisenberg AC, Lamarre L, Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. Cancer 1988;62:1893–1898.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Antin JH, Shulman LN, Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998;91:717–723.
   PubMed Web of Science ®Google Scholar
• Calaminici M, Piper K, Lee AM, CD23 expression in mediastinal large-cell lymphomas. Histopathology 2004;45:619–624.
   PubMed Web of Science ®Google Scholar
• Choi WW, Weisenburger DD, Greiner TC, A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494–5502.
   PubMed Web of Science ®Google Scholar
• Yamagata T, Nishida J, Tanaka S, A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol Cell Biol 1996;16:1283–1294.
   PubMed Web of Science ®Google Scholar
• Chang CC, McClintock S, Cleveland RP, Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464–470.
   PubMed Web of Science ®Google Scholar
• Saez AI, Saez AJ, Artiga MJ, Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 2004;164:613–622.
   PubMed Web of Science ®Google Scholar
• Colomo L, Lopez-Guillermo A, Perales M, Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78–84.
   PubMed Web of Science ®Google Scholar
• van Imhoff GW, Boerma EJ, van der Holt B, Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006;24:4135–4142.
   PubMed Web of Science ®Google Scholar
• Garcia-Cosio M, Santon A, Martin P, Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma. Mod Pathol 2004;17:1531–1538.
   PubMed Web of Science ®Google Scholar
• Emmerich F, Meiser M, Hummel M. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999;94:3129–3134.
   PubMed Web of Science ®Google Scholar
• Mendler JH, Kelly J, Voci S, Bortezomib and gemcitabine in relapsed refractory Hodgkin's lymphoma. Ann Oncol 2008;19:1759–1764.
   PubMed Web of Science ®Google Scholar